OPKO Health Gets $3 Target After Positive PK/PD in Oral LA-PTH Program
H.C. Wainwright reiterated a Buy rating on OPKO Health and set a $3 price target after OPKO expanded its co-development partnership with Entera Bio for an oral long-acting parathyroid hormone analog. Positive December 2025 PK/PD results back an IND filing planned for late 2026 with costs split 50/50.
1. H.C. Wainwright Rating and Price Target
H.C. Wainwright reiterated a Buy rating on OPKO Health and assigned a $3 price target, underscoring confidence in the company’s near-term growth catalysts tied to its pharmaceutical pipeline.
2. Strategic Collaboration with Entera Bio
OPKO’s subsidiary expanded its partnership with Entera Bio to co-develop an oral, long-acting parathyroid hormone analog for hypoparathyroidism, with each party holding a 50% ownership stake and sharing development costs equally.
3. Positive Preclinical Data and IND Timeline
Preclinical PK/PD data from December 2025 demonstrated robust bioavailability for the LA-PTH program, supporting plans to file an IND application by late 2026 to advance into clinical development.
4. Diversified Diagnostics and Pharmaceuticals Portfolio
OPKO Health operates BioReference Laboratories, one of the largest U.S. clinical labs, and markets RAYALDEE and NGENLA, positioning the company across diagnostics and specialty pharmaceuticals to drive diversified revenue growth.